Breast Cancer Research and Treatment

, Volume 134, Issue 1, pp 237–244

Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer

  • Sebastian F. Schoppmann
  • Anna Berghoff
  • Carina Dinhof
  • Raimund Jakesz
  • Michael Gnant
  • Peter Dubsky
  • Bettina Jesch
  • Harald Heinzl
  • Peter Birner
Preclinical study


While cancer research has been focused on tumor cells for many years, evidence is growing that the tumor stroma and in particular cancer-associated fibroblasts (CAFs) in particular play essential roles in the progression of human malignant disease. In human lung cancer, CAFs expressing the transmembrane protein podoplanin were shown to have significant influence on the patients’ prognosis. In this study, we investigated the presence and prognostic role of podoplanin-expressing CAFs in a large series of patients with invasive breast cancer. Podoplanin expression was evaluated immunohistochemically in 367 breast cancers. Tumors with ≥10% distinct podoplanin staining were considered as positive (CAF+). Cytoplasmic podoplanin expression of tumor cells was considered as positive when ≥5% of tumor cells showed a distinct podoplanin expression. In normal breast tissue, no podoplanin-expressing fibrocytes were found. Thirty-three patients (9%) with breast cancer showed podoplanin expression in CAFs. In 28 patients (8%), a podoplanin expression in tumor cells was observed. A strong negative correlation of CAF+ with estrogen receptor status (p < 0.001), and a significant association with higher histological grading (p < 0.001) was seen. In multivariable analysis, CAFs+ was an independent prognostic factor for disease free (1.78 Hazard ratio; p = 0.026) and overall survival (2.304 Hazard ratio; p = 0.002) in patients with breast cancer. Podoplanin-expressing CAFs contribute to the prognosis of invasive breast cancer, indicating a highly aggressive subgroup. CAFs may present a highly selective target for anti-cancer therapies in patients with invasive breast cancer.


Cancer-associated fibroblasts Breast cancer Metastasis Prognosis 


  1. 1.
    Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Kandioler-Eckersberger D, Gnant M, Jakesz R (2001) Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 7:1669–1675PubMedGoogle Scholar
  2. 2.
    Birner P, Obermair A, Schindl M, Kowalski H, Breitenecker G, Oberhuber G (2001) Selective immunohistochemical staining of blood and lymphatic vessels reveals independent prognostic influence of blood and lymphatic vessel invasion in early-stage cervical cancer. Clin Cancer Res 7:93–97PubMedGoogle Scholar
  3. 3.
    Breiteneder-Geleff S, Soleiman A, Horvat R, Amann G, Kowalski H, Kerjaschki D (1999) Podoplanin—a specific marker for lymphatic endothelium expressed in angiosarcoma. Verh Dtsch Ges Pathol 83:270–275PubMedGoogle Scholar
  4. 4.
    Elston CW, Ellis IO (2002) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 41:154–161. doi:1489_2[pii] PubMedCrossRefGoogle Scholar
  5. 5.
    Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795. doi:10.1200/JCO.2009.25.6529 PubMedCrossRefGoogle Scholar
  6. 6.
    Hasebe T, Sasaki S, Imoto S, Ochiai A (2000) Proliferative activity of intratumoral fibroblasts is closely correlated with lymph node and distant organ metastases of invasive ductal carcinoma of the breast. Am J Pathol 156:1701–1710. doi:10.1016/S0002-9440(10)65041-9 PubMedCrossRefGoogle Scholar
  7. 7.
    Hay ED, Zuk A (1995) Transformations between epithelium and mesenchyme: normal, pathological, and experimentally induced. Am J Kidney Dis 26:678–690. doi:0272-6386(95)90610-X[pii] PubMedCrossRefGoogle Scholar
  8. 8.
    Hofheinz RD, al-Batran SE, Hartmann F, Hartung G, Jager D, Renner C, Tanswell P, Kunz U, Amelsberg A, Kuthan H, Stehle G (2003) Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie 26:44–48. doi:10.1159/000069863ONK26044[pii] PubMedCrossRefGoogle Scholar
  9. 9.
    Hoshino A, Ishii G, Ito T, Aoyagi K, Ohtaki Y, Nagai K, Sasaki H, Ochiai A (2011) Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor formation: podoplanin in fibroblast functions for tumor progression. Cancer Res 71:4769–4779. doi:10.1158/0008-5472.CAN-10-3228 PubMedCrossRefGoogle Scholar
  10. 10.
    Jakesz R, Hausmaninger H, Haider K, Kubista E, Samonigg H, Gnant M, Manfreda D, Tschurtschenthaler G, Kolb R, Stierer M, Fridrik M, Mlineritsch B, Steindorfer P, Mittlbock M, Steger G (1999) Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer. J Clin Oncol 17:1701–1709PubMedGoogle Scholar
  11. 11.
    Jakesz R, Hausmaninger H, Samonigg H, Kubista E, Haider K, Mlineritsch B, Schmid M, Tausch C, Reiner G, Renner K, Stierer M, Jatzko G, Hofbauer F, Fridrik M, Schennach W, Sevelda P, Dadak C, Haid A, Scholz R, Lenzhofer P, Steindorfer P, Berger A, Mischinger HJ (1998) Therapy studies of the Austrian Breast Cancer Group (ABC). Zentralbl Chir 123(Suppl 5):28–32PubMedGoogle Scholar
  12. 12.
    Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6:392–401. doi:nrc1877[pii]10.1038/nrc1877 PubMedCrossRefGoogle Scholar
  13. 13.
    Kawase A, Ishii G, Nagai K, Ito T, Nagano T, Murata Y, Hishida T, Nishimura M, Yoshida J, Suzuki K, Ochiai A (2008) Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int J Cancer 123:1053–1059. doi:10.1002/ijc.23611 PubMedCrossRefGoogle Scholar
  14. 14.
    Kiely BE, Soon YY, Tattersall MH, Stockler MR (2011) How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. J Clin Oncol 29:456–463. doi:10.1200/JCO.2010.30.2174 PubMedCrossRefGoogle Scholar
  15. 15.
    Kim JB, Stein R, O’Hare MJ (2005) Tumour-stromal interactions in breast cancer: the role of stroma in tumourigenesis. Tumour Biol 26:173–185. doi:86950[pii]10.1159/000086950 PubMedCrossRefGoogle Scholar
  16. 16.
    Kimura N, Kimura I (2005) Podoplanin as a marker for mesothelioma. Pathol Int 55:83–86. doi:10.1111/j.1440-1827.2005.01791.x PubMedCrossRefGoogle Scholar
  17. 17.
    Kitano H, Kageyama S, Hewitt SM, Hayashi R, Doki Y, Ozaki Y, Fujino S, Takikita M, Kubo H, Fukuoka J (2010) Podoplanin expression in cancerous stroma induces lymphangiogenesis and predicts lymphatic spread and patient survival. Arch Pathol Lab Med 134:1520–1527. doi:10.1043/2009-0114-OA.1 PubMedGoogle Scholar
  18. 18.
    Kreppel M, Scheer M, Drebber U, Ritter L, Zoller JE (2010) Impact of podoplanin expression in oral squamous cell carcinoma: clinical and histopathologic correlations. Virchows Arch 456:473–482. doi:10.1007/s00428-010-0915-7 PubMedCrossRefGoogle Scholar
  19. 19.
    Olsen CJ, Moreira J, Lukanidin EM, Ambartsumian NS (2010) Human mammary fibroblasts stimulate invasion of breast cancer cells in a three-dimensional culture and increase stroma development in mouse xenografts. BMC Cancer 10:444. doi:10.1186/1471-2407-10-444 PubMedCrossRefGoogle Scholar
  20. 20.
    Potenta S, Zeisberg E, Kalluri R (2008) The role of endothelial-to-mesenchymal transition in cancer progression. Br J Cancer 99:1375–1379. doi:10.1038/sj.bjc.6604662 PubMedCrossRefGoogle Scholar
  21. 21.
    Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Badruddoja M, Dowell JM, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD (2006) Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol 24:115–122. doi:10.1200/JCO.2005.03.4082 PubMedCrossRefGoogle Scholar
  22. 22.
    Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343–346PubMedCrossRefGoogle Scholar
  23. 23.
    Schoppmann SF, Birner P, Studer P, Breiteneder-Geleff S (2001) Lymphatic microvessel density and lymphovascular invasion assessed by anti-podoplanin immunostaining in human breast cancer. Anticancer Res 21:2351–2355PubMedGoogle Scholar
  24. 24.
    Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, Divgi CR, Hanson LH, Mitchell P, Gansen DN, Larson SM, Ingle JN, Hoffman EW, Tanswell P, Ritter G, Cohen LS, Bette P, Arvay L, Amelsberg A, Vlock D, Rettig WJ, Old LJ (2003) A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 9:1639–1647PubMedGoogle Scholar
  25. 25.
    Shekhar MP, Werdell J, Santner SJ, Pauley RJ, Tait L (2001) Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. Cancer Res 61:1320–1326PubMedGoogle Scholar
  26. 26.
    Shibahara J, Kashima T, Kikuchi Y, Kunita A, Fukayama M (2006) Podoplanin is expressed in subsets of tumors of the central nervous system. Virchows Arch 448:493–499. doi:10.1007/s00428-005-0133-x PubMedCrossRefGoogle Scholar
  27. 27.
    Suzuki-Inoue K, Kato Y, Inoue O, Kaneko MK, Mishima K, Yatomi Y, Yamazaki Y, Narimatsu H, Ozaki Y (2007) Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem 282:25993–26001. doi:10.1074/jbc.M702327200 PubMedCrossRefGoogle Scholar
  28. 28.
    Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442–454. doi:10.1038/nrc822nrc822[pii] PubMedCrossRefGoogle Scholar
  29. 29.
    Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145. doi:10.1200/JCO.2006.09.2775 PubMedCrossRefGoogle Scholar
  30. 30.
    Yamanashi T, Nakanishi Y, Fujii G, Akishima-Fukasawa Y, Moriya Y, Kanai Y, Watanabe M, Hirohashi S (2009) Podoplanin expression identified in stromal fibroblasts as a favorable prognostic marker in patients with colorectal carcinoma. Oncology 77:53–62. doi:10.1159/000226112 PubMedCrossRefGoogle Scholar
  31. 31.
    Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R (2007) Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 67:10123–10128. doi:10.1158/0008-5472.CAN-07-3127 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2012

Authors and Affiliations

  • Sebastian F. Schoppmann
    • 1
  • Anna Berghoff
    • 2
  • Carina Dinhof
    • 3
  • Raimund Jakesz
    • 1
  • Michael Gnant
    • 1
  • Peter Dubsky
    • 1
  • Bettina Jesch
    • 1
  • Harald Heinzl
    • 4
  • Peter Birner
    • 5
  1. 1.Department of SurgeryGeneral Hospital, Medical University of ViennaViennaAustria
  2. 2.Institute of NeurologyMedical University of ViennaViennaAustria
  3. 3.University of Applied SciencesKremsAustria
  4. 4.Section for Clinical BiometricsMedical University of ViennaViennaAustria
  5. 5.Clinical Institute of PathologyMedical University of ViennaViennaAustria

Personalised recommendations